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Abstract
Objective—GM1 ganglioside has been suggested as a treatment for Parkinson’s disease (PD),
potentially having symptomatic and disease modifying effects. The current pilot imaging study
was performed to examine effects of GM1 on dopamine transporter binding, as a surrogate
measure of disease progression, studied longitudinally.
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Methods—Positron emission tomography (PET) imaging data were obtained from a subset of
subjects enrolled in a delayed start clinical trial of GM1 in PD1: 15 Early-start (ES) subjects, 14
Delayed-start (DS) subjects, and 11 Comparison (standard-of-care) subjects. Treatment subjects
were studied over a 2.5 year period while Comparison subjects were studied over 2 years.
Dynamic PET scans were performed over 90 minutes following injection of
[11C]methylphenidate. Regional values of binding potential (BPND) were analyzed for several
striatal volumes of interest.
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Results—Clinical results for this subset of subjects were similar to those previously reported for
the larger study group. ES subjects showed early symptomatic improvement and slow symptom
progression over the study period. DS and Comparison subjects were initially on the same
symptom progression trajectory but diverged once DS subjects received GM1 treatment. Imaging
results showed significant slowing of BPND loss in several striatal regions in GM1-treated subjects
and in some cases, an increased BPND in some striatal regions was detected after GM1 use.
Interpretation—Results of this pilot imaging study provide additional data to suggest a potential
disease modifying effect of GM1 on PD. These results need to be confirmed in a larger number of
subjects.
Keywords
Parkinson’s disease; GM1 ganglioside; PET; dopamine transporter; caudate; putamen
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1. Introduction
Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by loss
of dopamine-producing neurons in the substantia nigra pars compacta, loss of forebrain
dopamine (primarily in the caudate nucleus and putamen), and a progressive worsening of
clinical symptoms. Although improvement for many of the motor symptoms of the disease
can be obtained with available pharmacotherapies, functional ability continues to deteriorate
over time. Therefore, the development of disease modifying therapies is an area of intense
interest.
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GM1 ganglioside, a major constituent of neuronal plasma membranes, is associated with
specialized signaling domains called lipid rafts 23. GM1 modulates various cell activities
during development and plays important roles during adulthood in supporting neuronal
function and survival 4. GM1 is highly expressed in the adult brain 4 where it modulates
Ca2+ homeostasis5 and signal transduction, may promote lysosomal integrity6 and influence
mitochondrial function 7, 8. In a variety of preclinical studies, administration of GM1
following different types of lesions resulted in significant biochemical and behavioral
recovery 9-15, with results particularly impressive in animal models of PD 1614171819202122.
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Promising preclinical findings in animal models of PD have recently been translated to the
clinic. Since previous work suggested that GM1 might have both symptomatic and disease
modifying effects on PD 23, 24, a randomized, controlled, delayed start trial of GM1 in PD
patients was conducted 1. Subjects with mild/moderate PD were randomly assigned to
receive GM1 for 120 weeks (early-start (ES) group) or placebo for 24 wks. followed by
GM1 for 96 wks. (delayed-start (DS) group). Additional subjects who received standard-ofcare (Comparison group) were followed for 96 wks. to obtain information about disease
progression. At wk. 24, the ES group had significant improvement in the primary outcome
measure (i.e., change in Unified Parkinson’s Disease Rating Scale (UPDRS) motor score).
The DS group (as well as the standard-of-care Comparison group) showed a worsening of
scores during the same period. The ES group also showed a sustained benefit out to wk. 120
and their UPDRS scores remained below those recorded at study baseline 1. Subjects in both
treatment groups fared better than the Comparison group subjects. As part of this study, a
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subset of subjects who consented to undertake imaging studies were examined
longitudinally with positron emission tomography (PET) after the intravenous (IV) bolus
injection of [11C]methylphenidate ([11C]MP), which binds to and is used as a measure for
the concentration of the dopamine transporter (DAT). The decline of the binding potential
(BPND) of [11C]MP in the striatum of PD patients has been shown to be inversely correlated
with UPDRS scores and severity of motor disability 25 and has been suggested as a marker
of disease progression 25. The purpose of this imaging study was to evaluate potential
effects of GM1 treatment on the integrity of striatal dopamine terminals.

2. Subjects and Methods
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This study (ClinicalTrials.gov NCT00037830) was approved by the Division of Human
Subjects Protection at Thomas Jefferson University and by the Western IRB (Johns Hopkins
University). Written informed consent was obtained from all subjects prior to study.
Subjects enrolled in the main delayed start clinical trial (results reported previously 1) were
men or women between 39 and 85 years of age with a diagnosis of idiopathic PD consistent
with the UK PD Society brain bank PD diagnostic criteria. Details of inclusion/exclusion
criteria were discussed previously 1 and Comparison group subjects were recruited
according to the same criteria.

Author Manuscript
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PET imaging data were obtained from a subset of subjects enrolled in the main delayed start
clinical trial 1: 15 subjects from the ES group, 14 subjects from the DS group, and 11
subjects from the Comparison group. Treatment groups were scanned at baseline, at study
week 24 and at approximately one and two years after that. The Comparison group was
scanned at baseline and approximately one and two years later. Thermoplastic face masks
were constructed and individually fitted to each subject’s face for immobilization and
positioning for each MRI and PET scan as described by us previously 26. A transmission
scan of 10 minutes duration was obtained using rotating germanium-68 rods before injection
of the radiotracer. Subjects were scanned while in a practically defined “off” period as
described previously 1. Dynamic PET scans were performed over 90 minutes in a 3D mode
with a GE Advance PET scanner following an IV bolus injection of 740 megabecquerels
(MBq) [20 millicuries (20 mCi)] [11C]MP. Three series of structural MRIs of the brain
without contrast were performed 27 on a GE 1.5 T Signa MRI scanner. PET images were
reconstructed using the back projection algorithm with a ramp filter using the software
provided by the manufacturer correcting for attenuation, scatter, and dead-time. The
radioactivity was corrected for physical decay to the injection time. The final spatial
resolution of the PET images was estimated to be 5.5 and 6.1 mm full width at half
maximum (FWHM) in the radial and tangential directions, respectively, at 10 cm radius
from the center of the field-of-view 28. Volumes of interest (VOIs) were defined on
structural MRIs for the caudate nucleus (CN), putamen (PU), and cerebellum (Cb; both
hemispheres excluding white matter and the vermis) by an experienced, blinded rater (HK)
according to methods previously reported 29. VOIs were divided into associative striatum
(anterior putamen, aPu, and anterior and posterior caudate nucleus, aCN and pCN), motor
striatum (posterior putamen, pPu), and limbic or ventral striatum (vS) on left and right side
(a total of 10 VOIs) 30. VOIs were transferred from MRI to PET space according to MRI-toPET co-registration parameters (the co-registration module of the statistical parametric
J Neurol Sci. Author manuscript; available in PMC 2016 September 15.
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mapping (SPM) software; 31, available at http://www.fil.ion.ucl.ac.uk/spm/’) to obtain timeactivity curves (TACs). Regional values of BPNDs 32 were obtained by the multilinear
reference tissue method with 2 parameters (MRTM2) using the cerebellum as the reference
region 33 without applying any manipulations to TACs.
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Mixed effects linear regression (SAS v9.4, SAS Institute, Cary, NC) was used to
simultaneously model BPNDs for all 10 VOIs. Fixed effects were included for Group (ES,
DS, Comparison group), Time (0, 6, 12, 18, 24, and 30 months), and Region and all possible
interactions. An unstructured direct product covariance structure was assumed to model
correlation among the 10 VOIs measured at the same time and among the repeated
measurements across time. Within the mixed effects model, changes in BPNDs were
estimated and groups were compared with respect to change in BPNDs using appropriate
linear contrasts. Estimated mean BPND loss over time was calculated along with 95%
confidence limits. The analysis was intended to be exploratory and descriptive considering
the small number of subjects studied and P-values are provided for group comparisons
without adjustments for multiple comparisons.

3. Results
3.1 Subject Characteristics
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The baseline characteristics of the imaging sub-study subjects are shown in Table 1. There
were no significant group differences in most variables with the exception of time since
diagnosis, in which ES and DS subjects differed from the Comparison subjects (Table 1).
The baseline characteristics of the subjects participating in this imaging sub-study were
comparable to the entire group of subjects who participated in the main randomized delayed
start trial 1.
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The treatment effects in the subjects participating in the imaging sub-study were similar to
those described for the entire group of subjects who participated in the main randomized
delayed start trial 1. In the initial 24 wks. of the study (Phase I), subjects who received GM1
(ES subjects) showed improvement in UPDRS motor scores compared to subjects who
received placebo (DS subjects) and Comparison group subjects, whose UPDRS motor
scores worsened over the same time period (Figure 1). During the next phase of the study in
which all treatment subjects received GM1 (Phase II), ES subjects showed a slow
progression of symptoms, and by the end of the study, “off” period UPDRS motor scores
were approximately back to the level observed at study baseline (Figure 1). During this
second phase of the study, DS subjects showed an initial symptomatic benefit after
switching to GM1 and by the end of the study, their UPDRS motor scores were only slightly
higher than those observed at the end of the placebo period. The symptom progression
trajectory for the ES and DS groups was divergent at the end of the study, as in the larger
study group 1, suggestive of a possible disease-modifying effect of GM1.
3.2 [11C]methylphenidate ([11C]MP) Binding
The estimated mean fall in BPND from baseline was calculated for each VOI for each study
group. In these analyses, a negative number indicates a gain in BPND and a positive number
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indicates a loss of BPND. During the first 6 months of the study, there was less loss of BPND
in almost all regions (except the ventral striatum) in the ES group compared to the DS group
however this difference was statistically significant only in one region, the right posterior
putamen (Table 2). Six months may be too short a time interval in which to observe reliable
changes in the PET BPND or to observe potential disease modifying effects of GM1 therapy.
However, there was either no change or a gain of BPND in 7 of the 10 VOIs analyzed in the
ES group at 6 months vs. baseline while loss of BPND was measured in all VOIs in the DS
group (Table 2).
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The mean BPND loss from baseline to the next imaging study performed at 1 year into the
second phase of the study was also analyzed. At this point, the ES subjects had been on
GM1 for 18 months and the DS subjects had been on GM1 for 12 months. The Comparison
subjects were also scanned at 12 months following their baseline scans. Overall, the ES
subjects showed little loss of BPND after 18 months of GM1 use, compared to baseline and
for each region analyzed, and showed less loss of BPND compared to the DS subjects and
the Comparison group subjects (Table 3). There was less BPND loss in several striatal
regions in the ES group 18 months after baseline (and after 18 months of GM1 use) than in
the Comparison group over only a 12 month period (Table 3) and an apparent gain of BPND
was still detected in some regions in the ES subjects. Even though the DS group generally
showed less BPND loss in most striatal regions over a 12 month period of GM1 use
compared to the BPND loss in the Comparison group over 12 months, these differences were
not statistically significant (Table 3).
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The next data analyzed were the mean BPND loss from baseline to the end of year 2 of the
second phase of the study. At this point, the ES subjects had been on GM1 for 30 months
and the DS subjects had been on GM1 for 24 months. The Comparison subjects were also
scanned at 24 months following their baseline scans. In each region analyzed, there was less
BPND loss detected in the ES subjects at this time period compared to the DS subjects and
the Comparison group subjects. There was significantly less BPND loss in several striatal
regions in the ES group 30 months after baseline (and after 30 months of GM1 use) than in
the Comparison group over only a 24 month period (Table 4; Figure 2). In most regions, the
BPND loss in the DS subjects after 24 months of GM1 use was also less than that detected in
the Comparison group (Figure 2), although the difference was statistically significant only
for 1 region, the right posterior caudate nucleus (Table 4).

Author Manuscript

Taking the data collected at the 6 month point of the study as a new baseline for the DS
subjects (as they had been on placebo for the first 6 months of the study) we examined the
BPND loss between the 6 month time point and the end of the 2 year second phase of the
study. During this period, the DS subjects had used GM1 for 2 years. When analyzed this
way, the DS subjects showed less loss of BPND in all regions than did the Comparison
subjects over this 2 year period and the differences were statistically significant for 6 of the
10 regions analyzed (Table 5).
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4. Discussion
The results of this pilot study suggest the possibility of a slowing of BPND loss in several
striatal regions in GM1-treated subjects and in some cases, the data suggest an increased
BPND in some striatal regions, compared to baseline. There was less loss of BPND in ES
subjects versus the Comparison group, measured after 18 and 30 months of GM1 use. It is
possible that these results could have been affected by subjects in the Comparison group
having a slightly longer time since diagnosis compared to subjects in the ES and DS groups.
However, the decline in striatal dopamine transporter binding in early-stage PD patients
suggest no substantial differences in the rate of annual BP decline over the first 5 to 7 years
after symptom onset 34 ND. Also, once they switched to using GM1, the DS subjects also
showed less BPND loss over time than did Comparison group subjects, however, consistent
with the results of larger clinical study 1, there was an advantage to being in the ES group.
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There was an improvement in “off” UPDRS motor scores in GM1-treated subjects in Phase
I of the study and symptom worsening in placebo-treated subjects that mirrored the change
observed in the Comparison group. We previously suggested that the symptomatic effect
from GM1 in PD may relate to functional improvement in residual dopaminergic neurons, a
conclusion supported by data showing enhanced dopamine synthesis in residual dopamine
neurons in a mouse model of Parkinsonism following GM1 treatment 17. In Phase II, ES
subjects maintained some of the initial benefit of GM1 treatment and DS subjects showed
benefit after switching to GM1 use and both treatment groups fared better than the
Comparison subjects. We previously reported that such findings are suggestive of a potential
disease-modifying effect of GM1. If GM1 levels are decreased in the PD brain 35, 36 then
our GM1 replacement therapy may have provided a sufficient amount of GM1 to substantia
nigra neurons to stabilize them and promote their survival. Although the precise mechanisms
underlying the potential disease modifying effects of GM1 in PD are likely multi-factorial,
as suggested by us previously 1, recent work by Hadaczek et al. 36 suggest a new potential
neuroprotective role of GM1 based on its role in regulating GDNF signaling, a function
necessary for maintaining the health of dopaminergic neurons. GM1 was shown to be
required for assembly of the GDNF receptor and effective GDNF signaling was dependent
on an adequate level of GM1 36. This is relevant as studies with GDNF infusion in PD
patients have shown some clinical benefit as well as increases in putamenal 18F-dopa uptake
on PET and postmortem evidence of increased tyrosine hydroxylase immunopositive nerve
fibers, suggestive of terminal sprouting, in the infused putamen 37. The present imaging
results showing less loss of BPND in GM1 treated subjects in several striatal regions versus
Comparison subjects suggest improvement in imaging parameters as well as clinical status,
providing further support for a potential disease modifying effect of GM1 in PD.
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Preclinical studies with GM1 ganglioside in a variety of PD models, including MPTPtreated monkeys 14, have reported neuroprotective or neurorestorative effects of GM1 and
increased striatal dopamine and metabolite levels in GM1-treated animals as well as a
possible terminal sprouting effect in the striatum14, 22, 38, 39. GM1 administered to MPTPexposed monkeys resulted in a significant increase in 3H-mazindol binding to dopamine
transported sites in the striatum 19. Other studies also have reported increases in the
dopamine innervation of the striatum in GM1-treated animals with nigrostriatal
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lesions 16, 22. This, however, is the first clinical imaging study to suggest that GM1
administration to PD patients might slow the loss of dopamine terminals, detected by
measuring binding of [11C]MP to dopamine transporter sites, and perhaps at least in some
subjects in some striatal regions, even increase the number of dopamine terminals. These
data are consistent with the findings from GDNF infusion studies mentioned above.
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Previous studies (CALM-PD-CIT 40, REAL-PET41) have suggested a slowing in disease
progression based on either SPECT imaging of the dopamine transporter (CALM-PD)
or 18F-dopa positron emission tomography (REAL-PET) in PD patients taking pramipexole
or ropinirole, respectively, compared to patients taking levodopa. Although results from
these imaging studies suggested that both pramipexole and ropinirole were potentially
neuroprotective (i.e., both studies reported a slower loss of BPND over time in subjects with
agonist treatment compared to subjects receiving L-dopa), the imaging findings were not
supported by clinical observations of the subjects. Several potential reasons for the
discrepancy between clinical and imaging findings in these studies have been suggested
including confounding of UPDRS scores by anti-PD medications despite patient evaluations
in a “defined off” state 40 and drug-related differences in dopamine transporter binding
regulation 42, as the dopamine transporter is a highly regulated protein 43. The effects of
levodopa and ambient dopamine levels on dopamine transporter binding are unclear 44.
Striatal dopamine transporter levels may be up-regulated in a state of synaptic dopamine
excess and down-regulated in a dopamine-deficient condition, with the latter serving to
maximize the efficacy of the remaining dopamine. However, under some conditions the
dopamine transporter might actually be down-regulated by a treatment that enhances
dopaminergic function in the human 44. It is unlikely that the effects observed in the current
study can be substantially attributed to effects of levodopa on dopamine transporter
regulation. However, it is possible that improved dopamine neurotransmission in GM1treated subjects may have had an effect on dopamine transporter binding.
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This study has several potential limitations. This pilot imaging sub-study as well as the
overall clinical trial was conducted only at a single site. Only a small number of subjects
enrolled in the larger clinical study consented to participate in the imaging study and thus
there may have been some selection bias and systematic differences between the groups.
However, subjects in the two treatment groups were very well matched and only mean time
since diagnosis, a rather imprecise measure, was significantly different between the three
study groups at baseline. The time from diagnosis to participation in this study was longer
for subjects in the Comparison group compared to the subjects in the treatment groups.
While this may suggest that these subjects were studied at a slightly different point in the
course of their disease, time from diagnosis is an imprecise measure of disease duration.
Arguing against a significant clinical difference between the groups is the finding that
Comparion group subjects and DS subjects (receiving placebo) showed the same rate of
symptom progression during the first 6 months of the study. Due to the small number of
subjects studied and the pilot nature of the study, our analysis is mainly descriptive and
exploratory. P-values are provided for group comparisons but were not adjusted for multiple
testing and as such, statistical significance should be interpreted with caution. This study
also utilized subjects already receiving anti-PD medications, including dopamine agonists
and levodopa, and use of these medications could have influence the imaging results.
J Neurol Sci. Author manuscript; available in PMC 2016 September 15.
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Although clinical results were obtained and imaging studies were performed during a
practically defined “off” period, it is possible that long-lasting effects of these medications
on dopamine neurotransmission and the dopamine transporter site may have contributed to
some of the present findings. However, there was no significant difference between the
groups in regard to levodopa or dopamine agonist use. An additional limitation is the choice
of the PET radioligand [11C ]MP and its targeting of DAT. While MP is not the most
selective and highest affinity ligand for DAT (in comparison with tropanes, for example
[11C] Win 35,428 45, [123I]CIT, [11C]Altropane), it was chosen in part because its reversible
kinetics did not require a radial arterial input function with radioactive plasma
measurements and metabolites assessment. Also the measurement of DAT by any PET or
SPECT radioligand could be modulated by endogenous dopamine or medications.
Nevertheless MP is a well established radioligand for DAT measures and DAT is a well
established measure for evaluating the presynaptic dopamine system in PD.
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5. Conclusion
The clinical results of a previously reported delayed start trial of GM1 in PD 1, and results of
a previous 5 year open extension trial of GM1 in PD 24 suggest that long term use of GM1
may result in a slower than expected progression of symptoms. The current PET imaging
findings, although preliminary, provide additional data to suggest a potential disease
modifying effect of GM1 on PD. These preliminary results need to be confirmed in a larger
number of subjects and within the context of a larger, multi-center study.
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Highlights
•

PET imaging data were obtained from subjects enrolled in a trial of GM1 in PD.

•

Striatal [11C]methylphenidate binding potential values (BPND) were analyzed.

•

GM1 use was associated with slowed symptom progression.

•

Imaging results showed significant slowing of BPND loss in several striatal
regions.

•

Results provide additional data supporting a disease modifying effect of GM1
on PD.
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Figure 1.

Changes in Unified Parkinson’s Disease Rating Scale (UPDRS) Motor Subsection Scores
for the subset of subjects participating in the imaging study. The mean (±SEM) change from
baseline (observed scores) in Early-start (N = 15) and Delayed-start (N = 14) sub-study
subjects and in the standard-of-care Comparison group (N = 11), assessed in the practically
defined “off” condition. The dashed vertical line at week 24 indicates the end of study Phase
I. The dashed vertical line at week 120 indicates the end of study Phase II. The horizontal
dashed line indicates baseline level. An increase of score indicates symptom worsening; a
decrease in score indicates symptom improvement.
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Figure 2.

Averaged striatal binding potential images at baseline (Week 0 for the Comparison group
(C) subjects (N = 11)) [left panel] and at the transition point in the delayed start study (Week
24 for Delayed-start (DS: N = 14) [middle panel] and Early-start (ES: N = 15) [right panel]
groups) (top row) and averaged images obtained 2 years later at the end of the second phase
of study during which all treatment subjects used GM1 ganglioside. Images show less loss
of BPND over time in ES subjects and DS subjects versus Comparison group subjects. The
far right panel demonstrates the averaged images of the MRIs of all participants.
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Author Manuscript

Subject Demographics and Baseline Characteristics
Early-Start
(n=15)

Delayed-Start
(n=14)

Comparison
(n=11)

P value1

60.0 (8.9)

59.9 (9.4)

59.0 (12.8)

0.9652

Male

11 (73.3)

9 (64.3)

10 (90.9)

0.3158

Female

4 (26.7)

5 (35.7)

1 (9.1)

Age (years)
Sex: n (%)

1.8 (1.1)

2.4 (2.0)

5.0 (3.9)

1.5, 0.5 – 3.9

1.5, 0.4 – 6.1

3.8, 1.5 – 13.2

MMSE score

29.0 (1.0)

28.6 (1.3)

29.5 (0.9)

0.1483

BDI-II score

4.7 (2.8)

5.4 (3.3)

3.8 (2.9)

0.4758

Total UPDRS score (Off)

29.3 (8.3)

28.7 (10.3)

36.7 (10.8)

0.1493

UPDRS Motor score (Off)

19.3 (6.9)

20.6 (6.4)

24.3 (6.7)

0.0760

UPDRS ADL score (Off)

8.4 (3.2)

9.1 (4.1)

10.6 (4.5)

0.3770

UPDRS Mentation score (Off)

0.6 (1.3)

0.6 (0.8)

0.8 (1.1)

0.8136

Levodopa (# of subjects (percent))

10 (66.7)

10 (71.4)

8 (72.7)

0.1681

Dopamine Agonist* (# of subjects (percent))

10 (66.7)

9 (64.3)

9 (81.8)

0.8093

Selegiline (# of subjects (percent))

5 (33.3)

5 (35.7)

4 (36.4)

0.4686

Levodopa Equivalent Dose (mg/d)

300.8 (183.4)

420.3 (274.3)

544.1 (239.0)

0.0611

Mean time since diagnosis (years)
Median, Range (years)

0.0055

Author Manuscript

Medication Usage

Author Manuscript

Data presented as mean ± SD, unless otherwise noted. Levodopa equivalent dose calculations exclude 1 Comparison group subject who was
unmedicated at baseline.
*

Dopamine agonists included pramipexole, ropinirole, pergolide and bromocriptine.

1

P value was from one-way ANOVA for continuous variables and Kruskal-Wallis test for categorical variables for testing the differences between
Early-Start, Delayed-Start and Comparison groups.
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Author Manuscript

Estimated Mean BPND Loss (95% CI) From Baseline to End of Study Phase I (6 Months).

Author Manuscript

Region

Early Start (N=15)

Delayed Start (N=14)

p

LtaCN

−0.04 (−0.14, 0.07)

0.07 (−0.02, 0.16)

0.11

LtaPu

−0.01 (−0.08, 0.07)

0.06 (−0.01, 0.12)

0.19

LtpCN

0.02 (−0.09, 0.14)

0.08 (−0.02, 0.18)

0.44

LtpPu

0.00 (−0.04, 0.04)

0.02 (−0.02, 0.06)

0.53

LtvS

−0.04 (−0.15, 0.08)

0.04 (−0.06, 0.14)

0.35

RtaCN

−0.01 (−0.09, 0.07)

0.09 (0.02, 0.16)

0.09

RtaPu

−0.01 (−0.05, 0.03)

0.04 (−0.00, 0.07)

0.08

RtpCN

0.01 (−0.08, 0.11)

0.07 (−0.01, 0.15)

0.38

RtpPu

−0.01 (−0.06, 0.05)

0.07 (0.02, 0.11)

0.04

RtvS

0.07 (−0.02, 0.15)

0.01 (−0.07, 0.09)

0.35

LtaCN – left anterior caudate nucleus; LtaPu = left anterior putamen; LtpCN = left posterior caudate nucleus; LtpPu = left posterior putamen; LtvS
= left ventral striatum; RtaCN = right anterior caudate nucleus; RtaPu = right anterior putamen; RtpCN = right posterior caudate nucleus; RtpPu =
right posterior putamen; RtvS = right ventral striatum. A negative number indicates gain in BPND.
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Table 3

Author Manuscript

Estimated Mean BPND Loss (95% CI) From Baseline to End of First 12 Months of Study Phase II for EarlyStart and Delayed Start Groups.

Author Manuscript

Region

Early-Start (ES)
(GM1 used for 18
mos)

Delayed-Start (DS)
(GM1 used for 12
mos)

Comparison (C)
(12 mos from Bx)

p, ES
vs. C

p, DS
vs. C

LtaCN

−0.01 (−0.11, 0.09)

0.10 (0.01, 0.19)

0.15 (0.04, 0.25)

0.030

0.194

LtaPu

0.06 (−0.01, 0.13)

0.10 (0.03, 0.17)

0.09 (0.01, 0.16)

0.564

0.645

LtpCN

0.01 (−0.11, 0.12)

0.06 (−0.05, 0.16)

0.08 (−0.04, 0.20)

0.391

0.581

LtpPu

0.02 (−0.02, 0.06)

0.04 (−0.00, 0.08)

0.05 (0.00, 0.09)

0.396

0.415

LtvS

−0.02 (−0.13, 0.09)

0.03 (−0.07, 0.13)

0.05 (−0.07, 0.16)

0.428

0.695

RtaCN

0.01 (−0.07, 0.08)

0.13 (0.05, 0.20)

0.10 (0.02, 0.19)

0.086

0.670

RtaPu

−0.01 (−0.05, 0.03)

0.05 (0.02, 0.09)

0.05 (0.01, 0.09)

0.049

0.560

RtpCN

0.01 (−0.08, 0.10)

0.09 (0.01, 0.18)

0.18 (0.08, 0.27)

0.016

0.046

RtpPu

0.01 (−0.05, 0.06)

0.06 (0.02, 0.11)

0.12 (0.07, 0.18)

0.002

0.013

RtvS

0.04 (−0.04, 0.13)

0.09 (0.01, 0.17)

0.06 (−0.03, 0.15)

0.799

0.982

LtaCN – left anterior caudate nucleus; LtaPu = left anterior putamen; LtpCN = left posterior caudate nucleus; LtpPu = left posterior putamen; LtvS
= left ventral striatum; RtaCN = right anterior caudate nucleus; RtaPu = right anterior putamen; RtpCN = right posterior caudate nucleus; RtpPu =
right posterior putamen; RtvS = right ventral striatum. A negative number indicates gain in BPND. Bx = Baseline (start of study). Early-Start (N
=15); Delayed-Start (N =14); Comparison (N =11). P-values were calculated for comparing change over 18 months in the DS and ES arms vs the
extrapolated change over 18 months in the comparison group (1.5 x change from Bx to 12 months).
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Table 4

Author Manuscript

Estimated Mean BPND Loss (95% CI) From Baseline to End of Study Phase II for Early-Start and Delayed
Start Groups.

Author Manuscript

Region

Early-Start (ES)
(GM1 used for 30
mos)

Delayed-Start (DS)
(GM1 used for 24
mos)

Comparison (C)
(24 mos from Bx)

p, ES
vs. C

p, DS
vs. C

LtaCN

0.06 (−0.04, 0.16)

0.16 (0.07, 0.26)

0.30 (0.16, 0.43)

0.002

0.035

LtaPu

0.09 (0.02, 0.16)

0.14 (0.07, 0.21)

0.18 (0.09, 0.28)

0.055

0.199

LtpCN

0.11 (−0.01, 0.22)

0.11 (0.00, 0.22)

0.21 (0.06, 0.36)

0.150

0.162

LtpPu

0.04 (−0.00, 0.08)

0.06 (0.02, 0.11)

0.07 (0.01, 0.12)

0.318

0.654

LtvS

0.00 (−0.11, 0.11)

0.10 (−0.01, 0.21)

0.17 (0.02, 0.31)

0.058

0.312

RtaCN

0.10 (0.02, 0.18)

0.16 (0.08, 0.24)

0.21 (0.11, 0.31)

0.032

0.173

RtaPu

0.02 (−0.02, 0.06)

0.06 (0.02, 0.10)

0.07 (0.02, 0.12)

0.093

0.553

RtpCN

0.11 (0.02, 0.21)

0.13 (0.05, 0.22)

0.29 (0.17, 0.41)

0.007

0.012

RtpPu

0.07 (0.02, 0.12)

0.13 (0.08, 0.18)

0.17 (0.10, 0.24)

0.005

0.099

RtvS

0.13 (0.04, 0.22)

0.15 (0.07, 0.23)

0.15 (0.04, 0.26)

0.500

0.669

LtaCN – left anterior caudate nucleus; LtaPu = left anterior putamen; LtpCN = left posterior caudate nucleus; LtpPu = left posterior putamen; LtvS
= left ventral striatum; RtaCN = right anterior caudate nucleus; RtaPu = right anterior putamen; RtpCN = right posterior caudate nucleus; RtpPu =
right posterior putamen; RtvS = right ventral striatum. A negative number indicates gain in BPND. Bx = Baseline (start of study). Early-Start (N
=15); Delayed-Start (N =14); Comparison (N =11). P-values were calculated for comparing change over 30 months in the DS and ES arms vs the
extrapolated change over 30 months in the comparison group (1.25 x change from Bx to 24 months).
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Table 5

Author Manuscript

Estimated Mean BPND Loss (95% CI) From End of Study Phase I (6 Months) to the End of Study Phase II.

Author Manuscript

Region

Delayed Start:
GM1 for 24 months
(Phase II start/end
difference)

Comparison
0 −24 months
difference

p-value
for DS
vs. C

LtaCN

0.09 (0.00, 0.18)

0.30 (0.16, 0.43)

0.012

LtaPu

0.08 (0.02, 0.14)

0.18 (0.09, 0.28)

0.080

LtpCN

0.03 (−0.07, 0.13)

0.21 (0.06, 0.36)

0.049

LtpPu

0.04 (0.01, 0.08)

0.07 (0.01, 0.12)

0.520

LtvS

0.06 (−0.04, 0.16)

0.17 (0.02, 0.31)

0.250

RtaCN

0.07 (0.00, 0.14)

0.21 (0.11, 0.31)

0.033

RtaPu

0.03 (−0.01, 0.06)

0.07 (0.02, 0.12)

0.210

RtpCN

0.07 (−0.01, 0.15)

0.29 (0.17, 0.41)

0.003

RtpPu

0.06 (0.02, 0.11)

0.17 (0.10, 0.24)

0.012

RtvS

0.14 (0.06, 0.22)

0.15 (0.04, 0.26)

0.900

LtaCN – left anterior caudate nucleus; LtaPu = left anterior putamen; LtpCN = left posterior caudate nucleus; LtpPu = left posterior putamen; LtvS
= left ventral striatum; RtaCN = right anterior caudate nucleus; RtaPu = right anterior putamen; RtpCN = right posterior caudate nucleus; RtpPu =
right posterior putamen; RtvS = right ventral striatum. A negative number indicates gain in BPND. Delayed-Start (N =14); Comparison (N =11)
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